192 related articles for article (PubMed ID: 20091666)
1. Interventions for bone disease in children with chronic kidney disease.
Geary DF; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2010 Jan; (1):CD008327. PubMed ID: 20091666
[TBL] [Abstract][Full Text] [Related]
2. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D compounds for people with chronic kidney disease requiring dialysis.
Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
Cochrane Database Syst Rev; 2009 Oct; (4):CD005633. PubMed ID: 19821349
[TBL] [Abstract][Full Text] [Related]
5. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
[TBL] [Abstract][Full Text] [Related]
6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D compounds for people with chronic kidney disease not requiring dialysis.
Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
Cochrane Database Syst Rev; 2009 Oct; (4):CD008175. PubMed ID: 19821446
[TBL] [Abstract][Full Text] [Related]
8. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
9. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
10. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
11. Interventions for preventing bone disease in kidney transplant recipients.
Palmer SC; McGregor DO; Strippoli GF
Cochrane Database Syst Rev; 2007 Jul; (3):CD005015. PubMed ID: 17636784
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
[TBL] [Abstract][Full Text] [Related]
14. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
[TBL] [Abstract][Full Text] [Related]
15. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
16. Interventions for preventing bone disease in kidney transplant recipients.
Palmer S; McGregor DO; Strippoli GF
Cochrane Database Syst Rev; 2005 Apr; (2):CD005015. PubMed ID: 15846740
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
18. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
[TBL] [Abstract][Full Text] [Related]
19. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163
[TBL] [Abstract][Full Text] [Related]
20. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
